CD274 and colorectal carcinoma: Future studies should discover strategies that determine how to convert a ‘non-immunogenic’ CRC into an ‘immunogenic’ CRC and improve the therapeutic response rate to anti-PD-1/PD-L1 mAbs in patients with pMMR/MSI-L mCRC and the optimal strategy for identifying CRC patients who will benefit from anti-PD-1/PD-L1 mAb therapy prior treatments in the clinic.